Eine Studie zum Vergleich von Talquetamab in Kombination mit Daratumumab oder in Kombination mit Daratumumab und Pomalidomid versus Daratumumab in Kombination mit Pomalidomid und Dexamethason bei Teilnehmern mit rezidiviertem oder refraktärem multiplem Myelom (MonumenTAL-3)
Eine randomisierte Phase-3-Studie zum Vergleich von Talquetamab in Kombination mit Daratumumab (SC) und Pomalidomid (Tal-DP) oder Talquetamab (SC) in Kombination mit Daratumumab SC (Tal-D) versus Daratumumab SC, Pomalidomid und Dexamethason (DPd), bei Teilnehmern mit Rezidiviertes oder refraktäres multiples Myelom, das mindestens 1 vorherige Therapielinie erhalten hat
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Erweiterter Zugriff
Kontakte und Standorte
Studienorte
-
-
-
Brussels, Belgien, 1090
- UZ Brussel
-
Edegem, Belgien, 2650
- UZA
-
Hasselt, Belgien, 3500
- Virga Jessa Ziekenhuis
-
Liège, Belgien, 4000
- CHC MontLegia
-
Ottignies, Belgien, 1340
- Clinique Saint Pierre
-
Yvoir, Belgien, 5530
- UCL Mont Godinne
-
-
-
-
-
Barretos, Brasilien, 14784 400
- Fundacao Pio XII
-
Belo Horizonte, Brasilien, 30150-221
- Santa Casa de Misericordia de Belo Horizonte
-
Brasília, Brasilien, 70390-140
- IDOR - Regional Brasilia
-
Caxias do Sul, Brasilien, 95070 560
- Fundacao Universidade de Caxias do Sul
-
Curitiba, Brasilien, 81520-060
- Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
-
Florianópolis, Brasilien, 88020 210
- Grupo ELORA Centro de Pesquisa e Ensino em Saude de Santa Catarina
-
Natal, Brasilien, 59062-000
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre, Brasilien, 90050-170
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Ribeirão Preto, Brasilien, 14051140
- Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto
-
Rio de Janeiro, Brasilien, 22775 001
- Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
-
Salvador, Brasilien, 41253-190
- IDOR - Regional Bahia
-
São Paulo, Brasilien, 01321-001
- Real e Benemerita Associacao Portuguesa de Beneficencia
-
São Paulo, Brasilien, 01308 901
- Sociedade Beneficente de Senhoras Hospital Sirio Libanes
-
São Paulo, Brasilien, 01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, Brasilien, 01323-000
- Hospital Paulistano
-
São Paulo, Brasilien, 04537 081
- Clinica Medica Sao Germano LTDA
-
São Paulo, Brasilien, 01401 002
- IDOR - Regional Sao Paulo
-
-
-
-
-
Beijing, China, 100034
- Peking University First Hospital
-
Beijing, China, 100006
- Peking Union Medical College Hospital
-
Changchun, China, 130021
- The First Hospital of Jilin University
-
Changsha, China, 410000
- The second Xiangya Hospital of Central South University
-
Chaoyang District, China, 100020
- Beijing Chaoyang Hospital
-
Chengdu, China, 610072
- Sichuan Academy of Medical Science Sichuan Provincial Peoples Hospital
-
Fuzhou, China, 350001
- Fujian Medical University Union Hospital
-
Guangzhou, China, 510080
- Guangdong Provincial People's Hospital
-
Guangzhou, China, 510710
- Sun Yat Sen University Cancer Center
-
Hangzhou, China, 310003
- The First Affiliated Hospital Zhejiang University College of Medicine
-
Nanjing, China, 210008
- Nanjing Drum Tower Hospital
-
Shanghai, China, 200065
- Tongji Hospital of Tongji University
-
Shanghai, China, 200434
- Shanghai Fourth People s Hospital
-
Shenzhen, China, 518036
- Peking University Shenzhen Hospital
-
Suzhou, China, 215006
- First Affiliated Hospital SooChow University
-
Tianjin, China, 300320
- Institute of Hematology & Blood Disease Hospital Chinese Academy of Medical Science
-
Tianjin, China, 300060
- Tianjin cancer hospital
-
Wuhan, China, 430030
- Tongji Hospital, Tongji Medical College of HUST
-
Zhengzhou, China, 450008
- Henan Cancer Hospital
-
-
-
-
-
Berlin, Deutschland, 12203
- Charite Campus Benjamin Franklin
-
Cologne, Deutschland, 50937
- Universitaetsklinikum Koeln
-
Hamburg, Deutschland, 22763
- Asklepios Klinik Altona
-
Heidelberg, Deutschland, 69120
- Universitaetsklinikum Heidelberg
-
Leipzig, Deutschland, 04103
- Universitaetsklinikum Leipzig
-
Mainz, Deutschland, 55131
- Universitätsmedizin der Johannes Gutenberg Universität
-
Würzburg, Deutschland, 97080
- Universitaetsklinikum Wuerzburg
-
-
-
-
-
Créteil, Frankreich, 94010
- APHP - Hopital Henri Mondor
-
Dijon, Frankreich, 21000
- CHU Dijon
-
Lyon, Frankreich, 69008
- Centre Leon Berard
-
Montpellier, Frankreich, 34295
- CHU de Montpellier - Hopital Saint-Eloi
-
Nantes, Frankreich, 44093
- CHU de Nantes hotel Dieu
-
Nice, Frankreich, 06202
- CHU HOPITAL DE L'ARCHET - Hematology
-
Paris, Frankreich, 75571
- CHU Hopital Saint Antoine
-
Pessac, Frankreich, 33604
- CHRU - Hôpital du Haut Lévêque - Centre François Magendie
-
Toulouse, Frankreich, 31059
- Institut Universitaire du cancer de Toulouse-Oncopole
-
-
-
-
-
Athens Attica, Griechenland, 115 28
- Alexandra General Hospital of Athens
-
Thessaloniki, Griechenland, 546 39
- Anticancer Hospital of Thessaloniki Theageneio
-
Thessalonikis, Griechenland, 570 10
- G Papanikolaou Hospital of Thessaloniki
-
-
-
-
-
Afula, Israel, 1834111
- Ha'Emek Medical Center
-
Be’er Ya‘aqov, Israel, 70300
- Shamir Medical Center Assaf Harofeh
-
Hadera, Israel, 3810101
- Hillel Yaffe Medical Center
-
Haifa, Israel, 31096
- Rambam Medical Center
-
Haifa, Israel, 31048
- Bnai Zion Medical Center
-
Haifa, Israel, 34362
- Carmel Medical Center
-
Jerusalem, Israel, 9103102
- Shaare Zedek Medical Center
-
Nahariya, Israel, 22100
- Galilee Medical Center
-
Petah Tikva, Israel, 49100
- Beilinson medical center
-
Ramat Gan, Israel, 52621
- Sheba Medical Center
-
Safed, Israel, 13100
- Ziv Medical Center
-
Tel Aviv, Israel, 6423906
- Sourasky (Ichilov) Medical Center
-
-
-
-
-
Ancona, Italien, 60126
- A.O. Universitaria Ospedali Riuniti di Ancona
-
Bari, Italien, 70124
- Policlinico di Bari
-
Bologna, Italien, 40138
- Azienda Ospedaliera Policlinico S. Orsola-Malpighi
-
Brescia, Italien, 25123
- Azienda Ospedaliera Spedali Civili di Brescia
-
Catania, Italien, 95123
- PO G.Rodolico, AOU Policlinico-Vittorio Emanuele Catania
-
Milan, Italien, 20162
- ASST Grande Ospedale Metropolitano Niguarda
-
Milan, Italien, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Padova, Italien, 35128
- Azienda Ospedaliera Universitaria di Padova
-
Palermo, Italien, 90146
- Ospedale Villa Sofia-Cervello
-
Pavia, Italien, 27100
- Fondazione IRCCS Policlinico San Matteo
-
Reggio Emilia, Italien, 42123
- Arcispedale Santa Maria Nuova - IRCCS
-
Roma, Italien, 00193
- Presidio Ospedaliero Santo Spirito in Sassia
-
San Giovanni Rotondo, Italien, 71013
- IRCCS Ospedale Casa Sollievo della Sofferenza
-
Torino, Italien, 10126
- A.O.U. Città della Salute e della Scienza
-
-
-
-
-
Bunkyō City, Japan, 113 8519
- Institute of Science Tokyo Hospital
-
Chiba, Japan, 260-8717
- Chiba Cancer Center
-
Fukuoka, Japan, 814-0180
- Fukuoka University Hospital
-
Gifu, Japan, 503-8502
- Ogaki Municipal Hospital
-
Gunma, Japan, 371-0034
- Gunma University Hospital
-
Hirakata, Japan, 573 1191
- Kansai Medical University Hospital
-
Hyōgo, Japan, 670-8540
- Japanese Red Cross Society Himeji Hospital
-
Kamakura-shi, Japan, 247-8533
- Shonan Kamakura General Hospital
-
Kashiwa, Japan, 277 8577
- National Cancer Center Hospital East
-
Koshigaya, Japan, 343-8555
- Dokkyo Medical University Saitama Medical Center
-
Kumamoto, Japan, 860-8556
- Kumamoto University Hospital
-
Kyoto, Japan, 603-8151
- Kyoto Kuramaguchi Medical Center
-
Matsumoto, Japan, 399-8701
- National Hospital Organization Matsumoto Medical Center
-
Niigata, Japan, 951-8566
- Niigata Cancer Center Hospital
-
Nishinomiya Shi, Japan, 663 8501
- Hyogo Medical University Hospital
-
Sapporo, Japan, 060-8648
- Hokkaido University Hospital
-
Sendai, Japan, 980 8574
- Tohoku University Hospital
-
Shiwa-gun, Japan, 028-3695
- Iwate Medical University Hospital
-
Suita, Japan, 565 0871
- The University of Osaka Hospital
-
Tokyo, Japan, 135 8550
- The Cancer Institute Hospital of JFCR
-
Ōtake, Japan, 739-0696
- National Hospital Organization Hiroshima-Nishi Medical Center
-
-
-
-
-
Dordrecht, Niederlande, 3318 AT
- Albert Schweitzer ziekenhuis-lokatie Dordwijk
-
Eindhoven, Niederlande, 5631 BM
- Maxima Medisch Centrum
-
Rotterdam, Niederlande, 3015
- Erasmus MC
-
-
-
-
-
Brzozów, Polen, 36-200
- Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza
-
Gdansk, Polen, 80 214
- Uniwersyteckie Centrum Kliniczne
-
Katowice, Polen, 40 519
- Pratia Onkologia Katowice
-
Kielce, Polen, 25 734
- Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
-
Krakow, Polen, 30 688
- Szpital Uniwersytecki w Krakowie
-
Lublin, Polen, 20090
- Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli
-
Olsztyn, Polen, 10-228
- Szpital Kliniczny MSWiA z Warminsko Mazurskim Centrum Onkologii w Olsztynie Oddzial Hematologii
-
Szczecin, Polen, 71-252
- Uniwersytecki Szpital Kliniczny Nr 1 PUM im prof Tadeusza Sokolowskiego w Szczecinie
-
Torun, Polen, 87 100
- Wojewodzki Szpital Zespolony im L Rydygiera w Toruniu
-
Warsaw, Polen, 02-781
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
Wroclaw, Polen, 50 367
- Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
-
-
-
-
-
Badalona, Spanien, 08916
- Hosp. Univ. Germans Trias I Pujol
-
Barcelona, Spanien, 08041
- Hosp. de La Santa Creu I Sant Pau
-
Barcelona, Spanien, 08036
- Hosp Clinic de Barcelona
-
Barcelona, Spanien, 08035
- Hosp Univ Vall D Hebron
-
El Palmar, Spanien, 30120
- Hosp. Univ. Virgen de La Arrixaca
-
Jerez de la Frontera, Spanien, 11407
- Hosp. de Jerez de La Frontera
-
León, Spanien, 24071
- Hosp. de Leon
-
Madrid, Spanien, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, Spanien, 28034
- Hosp. Univ. Ramon Y Cajal
-
Madrid, Spanien, 28006
- Hosp. Univ. de La Princesa
-
Madrid, Spanien, 28050
- Hosp Univ Hm Sanchinarro
-
Málaga, Spanien, 29010
- Hosp Virgen de La Victoria
-
Pamplona, Spanien, 31008
- Clinica Univ. de Navarra
-
Salamanca, Spanien, 37007
- Hosp Clinico Univ de Salamanca
-
San Cristóbal de La Laguna, Spanien, 38320
- Hosp. Univ. de Canarias
-
Valencia, Spanien, 46017
- Hosp. Univ. Dr. Peset
-
-
-
-
-
Busan, Südkorea, 602 812
- Dong-A University Hospital
-
Gyeonggi-do, Südkorea, 10408
- National Cancer Center
-
Incheon, Südkorea, 21565
- Gachon University Gil Medical Center
-
Jeollanam-do, Südkorea, 58128
- Chonnam National University Hwasun Hospital
-
Jeonju, Südkorea, 54907
- Jeonbuk National University Hospital
-
Seoul, Südkorea, 03080
- Seoul National University Hospital
-
Seoul, Südkorea, 05505
- Asan Medical Center
-
Seoul, Südkorea, 03722
- Severance Hospital Yonsei University Health System
-
Seoul, Südkorea, 06351
- Samsung Medical Center
-
Seoul, Südkorea, 06591
- The Catholic University of Korea Seoul St Marys Hospital
-
-
-
-
-
Kaohsiung City, Taiwan, 83301
- Kaohsiung Chang Gung Memorial Hospital
-
Kaohsiung City, Taiwan, 80756
- Kaohsiung Medical University Chung Ho Memorial Hospital
-
Taichung, Taiwan, 40447
- China Medical University Hospital
-
Tainan, Taiwan, 704
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 10048
- National Taiwan University Hospital
-
-
-
-
-
Brno, Tschechien, 625 00
- Fakultni nemocnice Brno
-
Hradec Králové, Tschechien, 500 05
- Fakultni nemocnice Hradec Kralove
-
Olomouc, Tschechien, 779 00
- Fakultni nemocnice Olomouc
-
Ostrava - Poruba, Tschechien, 708 52
- Fakultni Nemocnice Ostrava
-
Prague, Tschechien, 100 34
- Fakultni nemocnice Kralovske Vinohrady
-
Prague, Tschechien, 128 08
- Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie
-
-
-
-
-
Ankara, Türkei (türkiye), 06680
- Liv Hospital Ankara
-
Ankara, Türkei (türkiye), 06200
- Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Hematology Unit
-
Ankara, Türkei (türkiye), 06590
- Ankara University Medical Faculty
-
Antalya, Türkei (türkiye), 07100
- Antalya Egitim ve Arastirma Hastanesi
-
Istanbul, Türkei (türkiye), 34093
- Istanbul University Istanbul Medical Faculty
-
Istanbul, Türkei (türkiye), 34214
- Medipol Mega University Hospital
-
Istanbul, Türkei (türkiye), 34153
- Cerrahpasa Tip Fakultesi Prof. Dr. Murat Dilmener Hastanesi
-
Izmir, Türkei (türkiye), 35330
- Dokuz Eylul University Medical Faculty
-
Samsun, Türkei (türkiye), 55139
- Ondokuz Mayis University
-
-
-
-
Arizona
-
Tucson, Arizona, Vereinigte Staaten, 85719
- The University of Arizona Cancer Center
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72205
- University of Arkansas for Medical Sciences
-
-
Connecticut
-
Norwalk, Connecticut, Vereinigte Staaten, 06850
- Norwalk Hospital-oncology
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20007
- MedStar Georgetown University Hospital
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20037
- George Washington University
-
-
Florida
-
Hollywood, Florida, Vereinigte Staaten, 33021
- Memorial Healthcare System
-
Miami, Florida, Vereinigte Staaten, 33136
- University of Miami Health System
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60612
- University Of Illinois
-
-
Kansas
-
Westwood, Kansas, Vereinigte Staaten, 66205
- University of Kansas
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Tulane University Hospital & Clinics
-
New Orleans, Louisiana, Vereinigte Staaten, 70121-2429
- Ochsner Health System
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21205
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02118
- Boston University Medical Center
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Massachusetts General
-
Worcester, Massachusetts, Vereinigte Staaten, 01655
- University of Massachusetts Medical School
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- University of Michigan Health System
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455
- University Of Minnesota
-
-
Mississippi
-
Jackson, Mississippi, Vereinigte Staaten, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
St Louis, Missouri, Vereinigte Staaten, 63110-1032
- Washington University School Of Medicine
-
-
New Jersey
-
New Brunswick, New Jersey, Vereinigte Staaten, 08901
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
New York, New York, Vereinigte Staaten, 10016
- NYU Langone Health
-
Syracuse, New York, Vereinigte Staaten, 13210
- SUNY Upstate Medical University
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599
- University of North Carolina
-
Charlotte, North Carolina, Vereinigte Staaten, 28204
- Levine Cancer Institute, Carolinas HealthCare System
-
Charlotte, North Carolina, Vereinigte Staaten, 28204
- Novant Health 1
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157
- Wake Forest Baptist Medical Center
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27103
- Novant Health
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- University Hospitals Cleveland Medical Center
-
Columbus, Ohio, Vereinigte Staaten, 43214
- OhioHealth
-
Columbus, Ohio, Vereinigte Staaten, 43210
- The Ohio State University Wexner Medical Center - James Cancer Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107-4215
- Thomas Jefferson University
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten, 29425-8900
- Medical University of South Carolina
-
-
Tennessee
-
Memphis, Tennessee, Vereinigte Staaten, 38120
- Baptist Cancer Center
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- MD Anderson Cancer Center
-
Houston, Texas, Vereinigte Staaten, 77030
- Houston Methodist Hospital
-
Lubbock, Texas, Vereinigte Staaten, 79410
- Joe Arrington Cancer Research Treatment Center
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84112
- Huntsman Cancer Institute
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22903
- University of Virginia
-
Richmond, Virginia, Vereinigte Staaten, 23298
- Virginia Commonwealth University - Massey Cancer Center
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98109
- Fred Hutchinson Cancer Research Center
-
-
-
-
-
Blackpool, Vereinigtes Königreich, FY3 8NR
- Blackpool Victoria Hospital
-
Dundee, Vereinigtes Königreich, DD1 9SY
- Ninewells Hospital & Medical School
-
London, Vereinigtes Königreich, W12 0HS
- Hammersmith Hospital
-
Newcastle upon Tyne, Vereinigtes Königreich, NE7 7DN
- Newcastle Freeman Hospital
-
Nottingham, Vereinigtes Königreich, NG5 1PB
- Nottingham City Hospital
-
Plymouth, Vereinigtes Königreich, PL6 8DH
- University Hospitals Plymouth NHS Trust
-
Sutton, Vereinigtes Königreich, SM2 5PT
- Royal Marsden Hospital
-
Wolverhampton, Vereinigtes Königreich, WV10 0QP
- New Cross Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Documented multiple myeloma as defined: a) Multiple myeloma diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria and b) Measurable disease at screening as defined by any of the following: i) Serum M-protein level greater than or equal to (>=) 0.5 grams per deciliter (g/dL) (central laboratory); ii) Urine M-protein level >= 200 milligram (mg) per 24 hours (central laboratory); iii) Light chain multiple myeloma without measurable M-protein in the serum or the urine: serum immunoglobulin free light chain >= 10 milligram per deciliter (mg/dL) (central laboratory), and abnormal serum immunoglobulin kappa lambda free light chain ratio
- Relapsed or refractory disease as defined by: i) Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease by IMWG criteria greater than (>) 60 days after cessation of treatment; ii) Refractory disease is defined as less than (<) 25 percent (%) reduction in monoclonal paraprotein (M-protein) or confirmed progressive disease by IMWG criteria during previous treatment or less than or equal to (<=) 60 days after cessation of treatment
- Received at least 1 prior line of antimyeloma therapy including a proteasome inhibitor (PI) and lenalidomide. Participants who have received only 1 prior line of antimyeloma therapy must be considered lenalidomide-refractory (that is, have demonstrated progressive disease by IMWG criteria on or within 60 days of completion of lenalidomide-containing regimen). Participants who have received >=2 prior lines of antimyeloma therapy must be considered lenalidomide exposed
- Documented evidence of progressive disease based on investigator's determination of response by the IMWG criteria on or after their last regimen
- Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment
Exclusion Criteria:
- Contraindications or life-threatening allergies, hypersensitivity, or intolerance to study drug excipients
- Disease is considered refractory to an anti-cluster of differentiation 38 (CD38) monoclonal antibody as defined per IMWG consensus guidelines (progression during treatment or within 60 days of completing therapy with an anti-CD38 monoclonal antibody)
- Received prior pomalidomide therapy
- A maximum cumulative dose of corticosteroids to >=140 milligrams (mg) of prednisone or equivalent within 14-day period before the first dose of study drug
- Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required
- Plasma cell leukemia (per IMWG criteria) at the time of screening, Waldenström's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS syndrome), or primary amyloid light chain amyloidosis
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Arm A: Talquetamab Subcutaneous (SC) in Combination With Daratumumab SC and Pomalidomide (Tal-DP)
Participants will receive talquetamab and daratumumab as SC injections; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Upon sponsor notification, participants will enter the Long-Term Extension (LTE) Phase or Drug Access Long-term Extension (DA-LTE) Phase and will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent or any other criteria specified is fulfilled. |
Talquetamab will be administered subcutaneously.
Andere Namen:
Pomalidomide will be administered orally. Dexamethasone will be administered orally or intravenously. Daratumumab will be administered subcutaneously. |
|
Experimental: Arm B: Daratumumab in Combination With Pomalidomide and Dexamethasone (DPd)
Participants will receive daratumumab as SC injection; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Upon sponsor notification, participants will enter the Long-Term Extension (LTE) Phase or Drug-access Long-term Extension (DA-LTE) Phase and will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent or any other criteria specified is fulfilled. |
Pomalidomide will be administered orally. Dexamethasone will be administered orally or intravenously. Daratumumab will be administered subcutaneously. |
|
Experimental: Arm C: Talquetamab SC in Combination With Daratumumab SC (Tal-D)
Participants will receive talquetamab and daratumumab as SC injection; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Upon sponsor notification, participants will enter the Long-Term Extension (LTE) Phase or Drug-access Long-term Extension (DA-LTE) Phase and will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent or any other criteria specified is fulfilled. |
Talquetamab will be administered subcutaneously.
Andere Namen:
Dexamethasone will be administered orally or intravenously. Daratumumab will be administered subcutaneously. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression-Free Survival (PFS)
Zeitfenster: Up to 6 years 6 months
|
PFS is defined as time from the date of randomization to the first documentation of disease progression, or death due to any cause, whichever is reported first. |
Up to 6 years 6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall Response (Partial Response [PR] or Better)
Zeitfenster: Up to 6 years 6 months
|
Overall response (PR or better) is defined as percentage of participants who have a PR or better per International Myeloma Working Group (IMWG) criteria. |
Up to 6 years 6 months
|
|
Very Good Partial Response (VGPR) or Better Rate
Zeitfenster: Up to 6 years 6 months
|
VGPR or better rate is defined as the percentage of participants who achieve a VGPR or better according to IMWG response criteria. |
Up to 6 years 6 months
|
|
Complete Response (CR) or Better Rate
Zeitfenster: Up to 6 years 6 months
|
CR or better rate is defined as the percentage of participants who achieve CR or better according to IMWG response criteria. |
Up to 6 years 6 months
|
|
Overall Minimal Residual Disease (MRD) Negative CR
Zeitfenster: Up to 6 years 6 months
|
MRD-negative CR is defined as proportion of participants with CR or stringent CR who achieve MRD negativity at a threshold of 10^-5 at any timepoint after the first dose of study drug and before disease progression or start of subsequent antimyeloma therapy. |
Up to 6 years 6 months
|
|
Overall Survival (OS)
Zeitfenster: Up to 6 years 6 months
|
OS is defined as the time from the date of randomization to the date of the participant's death. |
Up to 6 years 6 months
|
|
Progression-free Survival on Next-line Therapy (PFS2)
Zeitfenster: Up to 6 years 6 months
|
PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as progressive disease as assessed by investigator on the first subsequent line of antimyeloma therapy, or death from any cause, whichever occurs first. |
Up to 6 years 6 months
|
|
Time to Next Therapy (TTNT)
Zeitfenster: Up to 6 years 6 months
|
TTNT is defined as the time from randomization to the start of subsequent antimyeloma treatment. |
Up to 6 years 6 months
|
|
Number of Participants with Adverse Events (AEs)
Zeitfenster: Up to 6 years 6 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 6 years 6 months
|
|
Number of Participants with AEs by Severity
Zeitfenster: Up to 6 years 6 months
|
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). |
Up to 6 years 6 months
|
|
Serum Concentrations of Talquetamab
Zeitfenster: Up to 6 years 6 months
|
Serum concentrations of talquetamab will be reported. |
Up to 6 years 6 months
|
|
Serum Concentrations of Daratumumab
Zeitfenster: Up to 6 years 6 months
|
Serum concentrations of daratumumab will be reported. |
Up to 6 years 6 months
|
|
Number of Participants with Presence of Anti-Drug Antibodies (ADAs) to Talquetamab
Zeitfenster: Up to 6 years 6 months
|
Number of participants with presence ADAs to talquetamab will be reported. |
Up to 6 years 6 months
|
|
Number of Participants With Presence of Anti-Drug Antibodies (ADAs) to Daratumumab
Zeitfenster: Up to 6 years 6 months
|
Number of participants with presence of ADAs to daratumumab will be reported. |
Up to 6 years 6 months
|
|
Time to Worsening in Symptoms, Functioning, and Overall Health-Related Quality of Life (HRQoL) as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q)
Zeitfenster: Up to 6 years 6 months
|
The MySIm-Q is a disease-specific PRO assessment complementary to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 item (EORTC-QLQ-C30). |
Up to 6 years 6 months
|
|
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by PROMIS Short Form Version 2.0 -Physical Functioning 8c
Zeitfenster: Up to 6 years 6 months
|
The Patient-reported Outcomes Measurement Information System (PROMIS) Short Form Version 2.0 -Physical Function 8c is an 8-item fixed--length short form derived from the PROMIS Physical Function item bank. |
Up to 6 years 6 months
|
|
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by EORTC-QLQ-C30
Zeitfenster: Up to 6 years 6 months
|
Time to worsening in symptoms, functioning, and HRQoL as assessed by EORTC-QLQ-C30 will be reported. |
Up to 6 years 6 months
|
|
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by PRO-CTCAE
Zeitfenster: Up to 6 years 6 months
|
The National Cancer Institute's (NCI) PRO-CTCAE is an item library of common AEs experienced by people with cancer that are appropriate for self-reporting of treatment tolerability. |
Up to 6 years 6 months
|
|
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
Zeitfenster: Up to 6 years 6 months
|
The EQ-5D-5L is a generic measure of health status. For purposes of this study, the EQ-5D-5L will be used to generate utility scores for use in cost-effectiveness analyses. |
Up to 6 years 6 months
|
|
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by Patient Global Impression - Severity (PGI-S)
Zeitfenster: Up to 6 years 6 months
|
The PGI-S will be used as an anchor, external criterion, to determine meaningful change in scores for the MySIm-Q and PROMIS SF PF 8c in this population. |
Up to 6 years 6 months
|
|
Change From Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q)
Zeitfenster: Baseline up to 6 years 6 months
|
The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30. |
Baseline up to 6 years 6 months
|
|
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by PROMIS Short Form Version 2.0 -Physical Functioning 8c
Zeitfenster: Baseline up to 6 years 6 months
|
The Patient-reported Outcomes Measurement Information System (PROMIS) Short Form Version 2.0 -Physical Function 8c is an 8-item fixed-length short form derived from the PROMIS Physical Function item bank. |
Baseline up to 6 years 6 months
|
|
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by EORTC-QLQ-C30
Zeitfenster: Baseline up to 6 years 6 months
|
Change from baseline in symptoms, functioning, and HRQoL as assessed by EORTC-QLQ-C30 will be reported. |
Baseline up to 6 years 6 months
|
|
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by PRO-CTCAE
Zeitfenster: Baseline up to 6 years 6 months
|
The National Cancer Institute's (NCI) PRO-CTCAE is an item library of common AEs experienced by people with cancer that are appropriate for self-reporting of treatment tolerability. |
Baseline up to 6 years 6 months
|
|
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
Zeitfenster: Baseline up to 6 years 6 months
|
The EQ-5D-5L is a generic measure of health status. For purposes of this study, the EQ-5D-5L will be used to generate utility scores for use in cost-effectiveness analyses. |
Baseline up to 6 years 6 months
|
|
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by Patient Global Impression - Severity (PGI-S)
Zeitfenster: Baseline up to 6 years 6 months
|
The PGI-S will be used as an anchor, external criterion, to determine meaningful change in scores for the MySIm-Q and PROMIS SF PF 8c in this population. |
Baseline up to 6 years 6 months
|
Mitarbeiter und Ermittler
Ermittler
- Studienleiter: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Neubildungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Hämatologische Erkrankungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Neubildungen, Plasmazelle
- Hämostasestörungen
- Paraproteinämien
- Bluteiweißstörungen
- Hämorrhagische Störungen
- Hämische und lymphatische Krankheiten
- Multiples Myelom
- Polycyclische Verbindungen
- Schwangerschaft
- Schwangerschaft
- Steroide
- Fusions-Ring-Verbindungen
- Steroide, fluoriert
- Schwangerschaften
- Dexamethason
- Pomalidomid
- Daratumumab
- Talquetamab
Andere Studien-ID-Nummern
- CR109082
- 2021-000202-22 (EudraCT-Nummer)
- 64407564MMY3002 (Andere Kennung: Janssen Research & Development, LLC)
- 2023-503467-41-00 (Registrierungskennung: EUCT number)
- 2023 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .